Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
After only 16 weeks of existence, foetuses hear and respond to music as long as it is emitted from their mother’s vagina. Foetuses respond to this stimulus by opening their mouths and pulling their tongues out as far as possible, making vocalisation movements – prior to the acquisition of language.
This is the main conclusion of the study conducted by the team of Institut Marquès, which boasts the collaboration of Alberto Prats, Professor of Anatomy and Human Embryology of the Faculty of Medicine of the University of Barcelona.
The study, entitled “Foetal facial expression in response to intravaginal music emission”, is published this week in the journal Ultrasound of the British Medical Ultrasound Society (BMUS).
According to Dr. Marisa López-Teijón, the Head of Assisted Reproduction at Institut Marquès and the principal researcher and author of the clinical study: “We have discovered that the formula for foetuses to hear like us is to emit music from the mother’s vagina. They barely hear the sound that reaches them through their mother’s abdomen: the soft tissues of the abdomen and the inside of the mother’s body absorb the soundwaves”.
To view the multimedia release go to:
http://www.multivu.com/players/English/7647351-how-foetuses-hear-musical-stimuli/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
HMR Weight Management Services (HMR), a subsidiary of Merck, has been named a No. 1 Best Fast Weight-Loss Diet in U.S. News & World Report’s Best Diets of 2016 rankings. This is the first year U.S. News has published the Best Fast Weight-Loss Diet category. HMR also held its position as the No. 2 Best Weight-Loss Diet in the annual rankings list for the second year in a row. HMR Programs focus on helping people lose weight quickly while teaching the healthy lifestyle skills needed for long-term weight management.
“HMR programs excel at providing the jump start many people need when beginning a healthier lifestyle program,” said Carol Addy, M.D. MMSc, Chief Medical Officer at HMR. “A common misconception is that losing weight quickly is not healthy, not sustainable, and will just lead to future weight re-gain. To the contrary, numerous clinical studies demonstrate that following a lifestyle change program which promotes fast initial weight loss can result in better long-term success.” Addy added, “On the HMR Program, people can lose weight without feeling hungry. Our programs achieve fast weight loss in a livable way by encouraging people to eat more and stay satisfied, which makes it easier to stick to the program in the short-term, and over the long haul.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7670751-hmr-program-named-best-weight-loss-diet/
With America’s nursing shortage and the soaring aging population, the nation’s largest senior living provider has launched a student loan reimbursement program with the goal of attracting more nurses to work in assisted living. Brookdale’s initiative comes as the U.S. Bureau of Labor Statistics projects the country’s nurse shortfall will exceed one million by 2022. People 65 and above are expected to comprise 16 percent of America’s population in 2020 and nearly 20 percent in 2030, compared to 13 percent in 2010, according to the U.S. Census Bureau. Brookdale operates more than 1,120 senior living communities in 47 states.
At Brookdale assisted living communities, nurses are hired as health and wellness directors, overseeing clinical services at a community including setting standards, leading health and wellness programming, and managing care associates. “This is a different kind of path than hospital nursing and it is a very important one,” said Kim Estes, senior vice president of clinical services for Brookdale. “Rather than providing hands-on care, these nurses shape the overall quality and content of care their community’s seniors receive on a daily basis.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7722156-brookdale-student-loan-program-nurses/
As brain health becomes an ever greater concern for people of all ages, the nation’s largest senior living provider is now guiding its residents on developing and putting into practice personalized brain health plans. Brookdale devised the new resident program with the help of a neuropsychologist specializing in brain health. The company is putting it into place at its independent and assisted living communities across the country.
Through the new initiative, Brookdale’s residents will be offered a four-session course that explains key factors in brain health through classroom learning and hands-on activities. Each participant will be guided on creating an individual brain health plan to use on a daily basis. The course was developed with the assistance of Dr. Paul Nussbaum, who is Board Certified in clinical and geropsychology with a specialty in neuropsychology. An adjunct professor of neurological surgery at the University of Pittsburgh, he is the author of “Save Your Brain.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7722157-brookdale-brain-health/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
